Pharvaris PHVS
$31.28 −$0.38 (-1.20%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $31.28 0.00%
Open$31.41
Prev close$31.66
Day range$30.43 – $31.99
Volume464.0K
Market cap$2.21B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in EUR
Revenue€0.00
Operating profit-€50.08M-26.3% YoY
Net profit-€47.41M-27.7% YoY
Diluted EPS-€0.67-11.7% YoY
Free cash flow-€42.22M-37.6% YoY
Operating cash flow-€42.22M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-62.8%
Return on assets-57.2%
Return on invested capital-62.7%
Current ratio9.89
Liabilities / assets10.2%
Cash & investments€282.73M
Total debt€430,277.00
Net cash (debt)€282.30M
This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.
Income statement
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Operating Revenue | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| Operating Expense | €50.08M | €50.79M | €44.27M | €169.82M | €47.60M |
| Selling and Admin Expenses | €17.66M | €15.79M | €14.11M | €45.34M | €13.46M |
| -General & Admin Expense | €17.66M | €15.79M | €14.11M | €45.34M | €13.46M |
| Research & Development | €32.42M | €35.00M | €30.16M | €124.48M | €34.14M |
| Operating Profit | -€50.08M | -€50.79M | -€44.27M | -€169.82M | -€47.60M |
| Net Non-Operating Interest Income (Expense) | €1.91M | €1.91M | €5.34M | €6.36M | €2.13M |
| Non-Operating Interest Income | €2.00M | €1.98M | – | – | – |
| Total Other Finance Costs | €93,498.00 | €72,599.00 | -€5.34M | -€6.36M | -€6.48M |
| Other Income (Expense) | €974,898.00 | €1.64M | – | -€10.25M | €394,364.00 |
| Gain on Sale of Security | €974,898.00 | €1.64M | – | -€10.25M | €394,364.00 |
| Pretax Profit | -€47.20M | -€47.24M | -€38.93M | -€173.71M | -€45.08M |
| Tax | €214,524.00 | €602,200.00 | €273,107.00 | €1.99M | €1.66M |
| Net Profit | -€47.41M | -€47.84M | -€39.20M | -€175.70M | -€46.74M |
| Profit from Continuing Operations | -€47.41M | -€47.84M | -€39.20M | -€175.70M | -€46.74M |
| Net Income to Parent Company | -€47.41M | -€47.84M | -€39.20M | -€175.70M | -€46.74M |
| Net Income to Common Stockholders | -€47.41M | -€47.84M | -€39.20M | -€175.70M | -€46.74M |
| Basic EPS | -€0.67 | -€0.70 | -€0.60 | -€2.97 | -€0.71 |
| Diluted EPS | -€0.67 | -€0.70 | -€0.60 | -€2.97 | -€0.71 |
Balance sheet
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Assets | €295.06M | €328.67M | €259.79M | €301.45M | €301.45M |
| Total Current Assets | €293.21M | €326.88M | €257.68M | €299.17M | €299.17M |
| Cash and Cash Equivalents & Short-Term Investments | €282.73M | €318.28M | €246.96M | €291.68M | €291.68M |
| -Cash and Cash Equivalents | €282.73M | €318.28M | €246.96M | €291.68M | €291.68M |
| Receivables | €5.98M | €5.27M | €4.98M | €4.55M | €4.55M |
| -Taxes Receivable | €5.98M | €5.27M | €4.98M | €4.55M | €4.55M |
| Prepaid Assets | €4.49M | €3.33M | €5.75M | €2.94M | €2.94M |
| Total Non-Current Assets | €1.86M | €1.79M | €2.10M | €2.29M | €2.29M |
| Net PPE | €1.11M | €1.21M | €1.36M | €1.40M | €1.40M |
| -Gross PPE | €1.72M | €1.80M | €1.82M | €1.81M | €1.81M |
| -Accumulated Depreciation | -€612,328.00 | -€584,985.00 | -€460,654.00 | -€409,286.00 | -€409,286.00 |
| Non-Current Deferred Assets | €746,063.00 | €579,111.00 | €747,532.00 | €887,352.00 | €887,352.00 |
| Total Liabilities | €30.09M | €27.86M | €23.46M | €30.18M | €30.18M |
| Total Current Liabilities | €29.66M | €27.38M | €22.92M | €29.60M | €29.60M |
| Payables | €5.30M | €2.79M | €3.67M | €6.06M | €6.06M |
| -Accounts Payable | €5.30M | €2.79M | €2.71M | €5.11M | €5.11M |
| -Total Tax Payable | €0.00 | €0.00 | €960,809.00 | €941,209.00 | €941,209.00 |
| Current Accrued Expenses | €13.99M | €16.45M | €12.08M | €11.92M | €11.92M |
| Short-Term Debt and Capital Lease Obligation | €173,658.00 | €192,395.00 | €206,311.00 | €200,213.00 | €200,213.00 |
| -Current Capital Lease Obligation | €173,658.00 | €192,395.00 | €206,311.00 | €200,213.00 | €200,213.00 |
| Total Non-Current Liabilities | €430,277.00 | €481,333.00 | €532,580.00 | €576,585.00 | €576,585.00 |
| Long Term Debt and Capital Lease Obligation | €430,277.00 | €481,333.00 | €532,580.00 | €576,585.00 | €576,585.00 |
| -Long Term Capital Lease Obligation | €430,277.00 | €481,333.00 | €532,580.00 | €576,585.00 | €576,585.00 |
| Total Equity | €264.97M | €300.81M | €236.33M | €271.27M | €271.27M |
| Stockholders' Equity | €264.97M | €300.81M | €236.33M | €271.27M | €271.27M |
| Capital Stock | €8.50M | €8.42M | €7.85M | €7.83M | €7.83M |
| -Common Stock | €8.50M | €8.42M | €7.85M | €7.83M | €7.83M |
| Additional Paid-In Capital | €916.07M | €905.06M | €795.29M | €792.55M | €792.55M |
| Retained Earnings | -€716.58M | -€668.58M | -€619.54M | -€579.60M | -€579.60M |
| Gains/Losses Not Affecting Retained Earnings | €56.99M | €55.90M | €52.73M | €50.50M | €50.50M |
Cash flow
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Operating Cash Flow | -€42.22M | -€37.80M | -€48.77M | -€137.07M | -€37.95M |
| Net cash flow from continuing operations | -€42.22M | -€37.80M | -€48.77M | -€137.07M | -€37.95M |
| Net Income from Continuing Operations | -€47.20M | -€47.24M | -€38.93M | -€173.71M | -€45.08M |
| Gain/Loss from Continuing Operations | -€2.17M | -€2.54M | -€4.11M | €11.74M | -€239,583.00 |
| Depreciation & Depletion & Amortization | €92,390.00 | €179,299.00 | €104,726.00 | €418,353.00 | €104,868.00 |
| Other Non-Cash Items | €87,450.00 | €73,189.00 | €75,826.00 | -€439,591.00 | -€29,121.00 |
| Change in Working Capital | €1.02M | €6.73M | -€10.61M | €7.62M | €4.87M |
| -Change in Receivables | -€457,186.00 | -€70,704.00 | -€286,166.00 | -€331,339.00 | -€389,161.00 |
| -Change in Payables and Accrued Expense | €4.74M | €4.09M | -€9.10M | €6.21M | €5.06M |
| -Change in Other Current Assets | -€3.26M | €2.71M | -€1.23M | €1.75M | €201,598.00 |
| Net cash flow from investing | €0.00 | -€26,907.00 | -€52,097.00 | -€164,619.00 | -€1,538.00 |
| Net Cash Flow from Continuing Investing Activities | €0.00 | -€26,907.00 | -€52,097.00 | -€164,619.00 | -€1,538.00 |
| Net PPE Purchase and Sale | €0.00 | -€26,907.00 | -€52,097.00 | -€164,619.00 | -€1,538.00 |
| Financing Cash Flow | €6.13M | €105.87M | -€61,514.00 | €160.61M | €271,491.00 |
| Net Cash Flow from Continuing Financing Activities | €6.13M | €105.87M | -€61,514.00 | €160.61M | €271,491.00 |
| Net Issuance Payments Of Debt | -€62,435.00 | -€62,038.00 | -€61,514.00 | -€219,013.00 | -€66,316.00 |
| Net Common Stock Issuance | €6.22M | €113.13M | €0.00 | €171.74M | €337,338.00 |
| Net Other Financing Charges | -€29,420.00 | – | – | -€10.91M | €469.00 |
| Ending Cash Balance | €282.73M | €318.28M | €246.96M | €291.68M | €291.68M |
| Net Change in Cash | -€36.09M | €68.05M | -€48.88M | €23.37M | -€37.68M |
| Beginning Cash Balance | €318.28M | €246.96M | €291.68M | €280.73M | €329.29M |
| Effect of Exchange Rate Changes | €537,548.00 | €3.28M | €4.16M | -€12.42M | €76,064.00 |
| Free Cash Flow | -€42.22M | -€37.83M | -€48.82M | -€137.24M | -€37.95M |
No comments yet — be the first to weigh in on PHVS.
Sign in to join the discussion.